A multicentre, randomised, double blind, parallel group study to compare the efficacy and safety of salmeterol/fluticasone propionate combination Product (Seretide) 50/100mcg with fluticasone propionate (Flixotide) 200mcg, both delivered twice daily via the DISKUS inhaler, in the treatment of children aged 6−12 years with symptomatic asthma.

Trial Profile

A multicentre, randomised, double blind, parallel group study to compare the efficacy and safety of salmeterol/fluticasone propionate combination Product (Seretide) 50/100mcg with fluticasone propionate (Flixotide) 200mcg, both delivered twice daily via the DISKUS inhaler, in the treatment of children aged 6−12 years with symptomatic asthma.

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Mar 2017

At a glance

  • Drugs Fluticasone propionate; Salmeterol/fluticasone propionate
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms COMBO
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 22 Sep 2010 Results were presented at the 20th Annual Congress of the European Respiratory Society.
    • 01 Apr 2009 Actual end date (Oct 2008) added, Planned number of patients changed from 200 to 176 as reported by ClinicalTrials.gov.
    • 01 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top